1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists


The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity.


In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.

The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.


The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product Category,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:


The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Table of Contents

1. Selective GLP-1 Analogs for Metabolic Diseases
2013 Sales of GLP-1 Analogs
Short-Acting Injectable GLP-1 Analogs
Long-Acting Injectable GLP-1 Analogs
Very Long-Acting Injectable GLP-1 Analogs
Oral Peptide-Based GLP-1 Analogs
Other Non-Injectable Peptide-Based GLP-1 Analogs
Oral Small Molecule GLP-1 Receptor Agonists

2. Selective GLP-1 Analogs for Non-Metabolic Diseases

3. Dual Target GLP-1 Analogs
GLP-1 and Insulin
GLP-1 and Glucagon
GLP-1 and GIP
GLP-1 and Gastrin/CCKB
GLP-1 and GLP-2

4. Corporate GLP-1 Receptor Agonist RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • March 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.